Actor Portrayals

Start patients on NUPLAZID® (pimavanserin) 34 mg—the only FDA-approved therapy proven to reduce delusions and hallucinations associated with PD psychosis in elderly patients.1,2

NUPLAZID 34 mg capsule

ONE FDA-approved treatment, ONE small* capsule, ONE daily dose

  • Reduces PD-related delusions and hallucinations without impacting motor function

  • Demonstrated safety profile in elderly patients with PD psychosis

  • In vitro, a serotonergic agent with no appreciable affinity for D2, histamine, muscarinic, or adrenergic receptors

 

*Actual size is 14.3 mm X 5.3 mm.
The maximum age in the clinical studies was 90 years old.3
The precise mechanism of action of NUPLAZID is unclear but is thought to be mediated through a combination of inverse agonist and antagonist activity. However, the effect of NUPLAZID could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.1

NUPLAZID is proven to reduce delusions and hallucinations associated with PD psychosis in elderly patients1,2

NUPLAZID showed continuous improvement over 6 weeks

NUPLAZID showed continuous improvement over 6 weeks

Results from a Phase 3, randomized, multicenter, double-blind, placebo-controlled, parallel-group study of PD psychosis patients (N=199).1,2 Primary endpoint was change from baseline at 6 weeks in the 9-item SAPS-PD. Doses of PD medications taken prior to baseline were required to be stable 30 days prior to study start and throughout the study period. Mean baseline score was 15.9 for NUPLAZID and 14.7 for placebo. The mean age of patients enrolled in the clinical study with NUPLAZID was 72 years.2 While the primary endpoint was designed to measure change from baseline to Week 6, a statistically significant difference between NUPLAZID and placebo was observed at Week 4 (P=0.0369) and again at Week 6 (P=0.0014).

LSM=least-squares mean; SAPS-PD=Scale for Assessment of Positive Symptoms-Parkinson’s Disease; SE=standard error.

 

running person outline

Treat PD-related delusions and hallucinations without impacting motor function1,2

NUPLAZID 34 mg did not impact motor function or motoric activities of daily living compared to placebo.*

*As measured by United Parkinson’s Disease Rating Scale Parts II and III (UPDRS II+III).

NUPLAZID has a demonstrated safety profile proven in elderly patients with PD psychosis1

 

80% of patients in NUPLAZID clinical trials were aged 65 years or older.

In the 6-week studies, the maximum age was 90 years.3

A single-capsule treatment1

fda

ONE treatment

  • The only FDA-approved therapy proven to reduce delusions and hallucinations associated with PD psychosis in elderly patients without impacting motor function

    • In the 6-week studies, 80% of patients were aged 65 years or older*

ONE small capsule

 

ONE small capsule

  • 34 mg in one single capsule

ONE daily dose

ONE daily dose

  • Taken orally, with or without food

    • No dosage adjustment of carbidopa/levodopa is required when administered concomitantly with NUPLAZID

 

*In the clinical trials, the maximum age of patients on NUPLAZID was 85 years old vs 90 years old for placebo.3 
Actual size is 14.3 mm X 5.3 mm.    

For healthcare professionals